Literature DB >> 3689047

Assessment of residual right ventricular outflow tract obstruction following surgery using the response to intravenous propranolol.

D F Wensley1, T Karl, J E Deanfield, M R de Leval, F J Macartney, J Stark.   

Abstract

The response to intravenous administration of propranolol hydrochloride was studied in 24 children undergoing operation for isolated or complex right ventricular outflow tract obstruction. Ten had pulmonary valve stenosis, 4 had pulmonary valve stenosis plus ventricular septal defect, 8 had tetralogy of Fallot, and 2 had complex lesions. Propranolol (0.01 to 0.2 mg per kilogram of body weight) was given to patients with a residual right ventricular to left ventricular systolic pressure ratio greater than 0.75. Four children did not respond to propranolol and required further surgical intervention. Twenty patients responded, 2 of whom died. Fifteen were restudied by cardiac catheterization 3 weeks to 27 months postoperatively. The right ventricle-pulmonary artery gradient was 25 mm Hg or less in 13 patients. We conclude that a small dose of propranolol given intraoperatively can identify patients in whom a reduction in the right ventricle-pulmonary artery gradient to acceptable levels will occur in the months following operation. This may reduce the need for placement of a subannular or transannular patch in some patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689047     DOI: 10.1016/s0003-4975(10)62151-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  The unnatural history of tetralogy of Fallot: surgical repair is not as definitive as previously thought.

Authors:  C van Doorn
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

2.  Incidence of adverse events requiring intervention after initiation of oral beta-blocker in pediatric cardiac intensive care patients.

Authors:  Jolie Britt; Brady S Moffett; Ronald A Bronicki; Paul A Checchia
Journal:  Pediatr Cardiol       Date:  2014-04-10       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.